Utilization of serial next-generation sequencing among patients receiving CPX-351 for newly diagnosed acute myeloid leukemia

The phase III trial that led to the approval of CPX-351 for treating secondary acute myeloid leukemia (sAML) in 2017 did not study the effect of specific mutations on outcomes. This retrospective study was done to evaluate the effect of next-generation sequencing (NGS) results at the time of best response and before allogeneic stem cell transplant (alloSCT) in patients treated with CPX-351 as frontline therapy for sAML between 2017 and 2021. The most common mutations seen were DNMT3A (n  = 17, 29.8%), SRSF2 (n = 13, 22.8%), RUNX1 (n = 13, 22.8%), TET2 (n = 9, 15.8%), ASXL1 (n = 9, 15.8%), and BCOR (n = 9, 15.8%).

Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2023 Category: Hematology Authors: Akriti G Jain, Somedeb Ball, Luis E Aguirre, Katherine A Tobon, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, David Sallman, Jeffrey E Lancet, Kendra Sweet Tags: Original Study Source Type: research